Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2007-04-10
2007-04-10
Henley, III, Raymond J. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C514S249000, C514S356000, C514S565000
Reexamination Certificate
active
10920395
ABSTRACT:
A method of stimulating the expression of endothelial NO-synthase in a mammal, which method comprises administering a physiologically active amount of 4-fluoro-N-indan- 2-yl benzamide according to the formula (I)to the said mammal. Compound (I) can be used for the therapy and prophylaxis of cardiovascular diseases like stable and unstable angina pectoris, Prinzmetal angina (spasm), acute coronary syndrome, heart failure, myocardial infarction, stroke, thrombosis, peripheral artery occlusive disease PAOD, atherosclerosis, restenosis, endothelial damage after PTCA, essential hypertension, pulmonary hypertension, secondary hypertension, renovascular chronic glomerulonephritis, erectile dysfunction, ventricular arrhythmia, and the lowering of cardiovascular risk of postmenopausal women or after intake of contraceptives, the therapy and prophylaxis of diabetes and diabetes complications (nephropathy, retinopathy), angiogenesis, asthma bronchiale, chronic renal failure, cirrhosis of the liver, restricted memory performance or a restricted ability to learn.
REFERENCES:
patent: 6376509 (2002-04-01), Bakshi et al.
patent: 6617359 (2003-09-01), Wohlfart et al.
patent: 6759412 (2004-07-01), Strobel et al.
patent: 6812253 (2004-11-01), Wohlfart et al.
patent: 6949556 (2005-09-01), Strobel et al.
patent: 2003/0008915 (2003-01-01), Strobel et al.
patent: 2003/0022935 (2003-01-01), Strobel et al.
patent: 2003/0055093 (2003-03-01), Strobel et al.
patent: 2004/0082628 (2004-04-01), Strobel et al.
patent: 2004/0092513 (2004-05-01), Strobel et al.
patent: 2004/0110808 (2004-06-01), Strobel et al.
patent: 2004/0225013 (2004-11-01), Strobel et al.
patent: 2005/0101599 (2005-05-01), Zeiher et al.
patent: WO 99/47153 (1999-09-01), None
patent: WO 99/47153 (1999-09-01), None
patent: WO 00/03746 (2000-01-01), None
patent: WO 00/51970 (2000-09-01), None
Matthias Endres et al., Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase, Proc. Natl. Acad. Sci. USA, Jul. 1998, vol. 95, pp. 8880-8885.
Huige Li et al., Activation of Protein KinaseCaand /or ε Enhances Transcription of the Human Endothelial Nitric Oxide Synthase Gene, Molecular Pharmacology (1998) 53:630-637.
M. F. McCarty, Up-regulation of endothelial nitric oxide activity as a central strategy for prevention of ischemic stroke—Just say NO to stroke!, Medical Hypotheses (2000) 55(5), 386-403.
Masao Moroi et al., Interaction of Genetic Deficiency of Endothelial Nitric Oxide, Gender, and Pregnancy in Vascular Response to Injury in Mice, The Journal of Clinical Investigation, Mar. 1998, vol. 101, No. 6, 1225-1232.
Masafumi Nakayama et al., T788→ C Mutation in the 5' -Flanking Region of the Endothelial Nitric Oxide Synthase Gene is Associated With Coronary Spasm, Clinical Investigation and Reports (1999) 2864-2870.
William C. Sessa et al., Chronic Exercise in Dogs Increases Coronary Vascular Nitric Oxide Production and Endothelial Cell Nitric Oxide Synthase Gene Expression, Circulation Research, 1994, vol. 74, No. 2, 349-353.
Olivier Varenne et al., Percutaneous Gene Therapy Using Recombinant Adenoviruses Encoding Human Herpes Simplex Virus Thymidine Kinase, Human PAI-1, and Human NOS3 in Balloon-Injured Porcine Coronary Arteries, Human Gene Therapy (Jun. 10, 2000) 11:1329-1339.
Dharanipragada Ramalinga M.
Safarova Alena
Strobel Hartmut
Suzuki Teri
Walser Armin
Finnegan, Henderson Farabow, Garrett and Dunner L.L.P.
Henley III Raymond J.
Sanofi-Aventis Deutschland GmbH
LandOfFree
4-fluoro-N-indan-2-yl benzamide and its use as a pharmaceutical does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 4-fluoro-N-indan-2-yl benzamide and its use as a pharmaceutical, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 4-fluoro-N-indan-2-yl benzamide and its use as a pharmaceutical will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3731031